Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan + zanzalintinib versus cabozantinib in advanced renal cell carcinoma after recurrence during or after adjuvant PD-1/L1 therapy
2024-517136-21-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Dec 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial in renal cell carcinoma (RCC) comparing Belzutifan + zanzalintinib with Cabozantinib (2 arms). Primary endpoints: Progression-free survival and Overall survival. Planned start Dec 2025; status: authorised.
02
Drugs
belzutifanzanzalintinibcabozantinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2024-517136-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517136-21-00.